Breaking News

AbbVie To Establish Manufacturing Ops in Singapore

By Kristin Brooks | February 6, 2014

To invest $320 million in capacity for oncology and immunology pipeline

AbbVie is investing $320 million to establish manufacturing operations in Singapore for small molecule and biologics active drug substance. Once completed, the facility will provide manufacturing capacity for compounds in AbbVie's oncology and immunology pipeline to serve global markets. The investment is expected to result in additional headcount of more than 250 new employees. AbbVie anticipates the facility will be fully operational by 2019.
AbbVie’s operations in Asia currently include R&D functions in Tokyo, Japan and Shanghai, China, as well as commercial operations throughout the region. AbbVie currently employs 120 personnel in Singapore, supporting commercial operations, global R&D, and general operations.
"As Asia's fastest-growing bio-cluster, Singapore is an ideal location to expand our manufacturing network while maintaining rigorous standards of quality and delivery for the patients we serve around the world," said Azita Saleki-Gerhardt, Ph.D., senior vice president, Operations, AbbVie. "Our presence in Singapore will help assure geographic balance and continuity of product supply as well as increased capacity to deliver on our growing biologics and small molecule product pipeline."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision